Dr Reddy's ties up with Gilead to manufacture, commercialise HIV drug

Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of the HIV drug Lenacapavir in India and 120 other countries.

The company has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the drug, the Hyderabad-based drug maker said in a statement.

Lenacapavir is a US Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus a type 1 (HIV-1) infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.

Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally.

Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the US and Europe markets in the year 2022.

As per the agreement, Dr Reddy's w